SCHEMBL5260555

SCHEMBL5260555

CNc1nccc(-c2cccnc2Oc2ccc(F)c(C(=O)Nc3cc(C(F)(F)F)cc(Cl)c3NCCCCN(C)C)c2)n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 15/20 0.72
KDR P35968 10/20 0.72
AURKA O14965 4/20 0.60
ABL1 P00519 2/20 0.60
LCK P06239 2/20 0.60
CSF1R P07333 2/20 0.60
SRC P12931 2/20 0.60
MAPK14 Q16539 2/20 0.60
EGFR P00533 1/20 0.60
NTRK1 P04629 1/20 0.60
INSR P06213 1/20 0.60
FES P07332 1/20 0.60
LYN P07948 1/20 0.60
RET P07949 1/20 0.60
IGF1R P08069 1/20 0.60
MET P08581 1/20 0.60
PDGFRB P09619 1/20 0.60
FGR P09769 1/20 0.60
AKT1 P31749 1/20 0.60
CSK P41240 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1264166 0.89 TEK (0.80) TEKKDRAURKAABL1LCK
SCHEMBL2296040 0.84 TEK (0.66) TEKKDRAURKAABL1LCK
SCHEMBL1265824 0.84 TEK (1.00) TEKKDRAURKAABL1LCK
SCHEMBL1265034 0.83 TEK (0.92) TEKKDRAURKAABL1LCK
SCHEMBL1265236 0.82 TEK (0.77) TEKKDRAURKAABL1LCK
SCHEMBL1265895 0.81 TEK (0.66) TEKKDRAURKAABL1LCK
SCHEMBL1265767 0.81 TEK (0.75) TEKKDRAURKAABL1LCK
SCHEMBL1264910 0.81 TEK (0.84) TEKKDRAURKAABL1LCK
SCHEMBL1265791 0.81 TEK (0.90) TEKKDRAURKAABL1LCK
SCHEMBL1264710 0.80 TEK (0.90) TEKKDRAURKAABL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751136-A2 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC. (US) 2007-02-14 EP disclosed
WO-2005113494-A2 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC. (US) 2005-12-01 WO disclosed